Professor Jeffrey Lipman

Conjoint Professor

Royal Brisbane Clinical Unit
Faculty of Medicine
+61 7 334 65015
+61 7 3646 1847


Prof Lipman is Executive Director of the Burns Trauma & Critical Care Research Centre; Director of Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital; Professor of Anesthesiology & Critical Care, The University of Queensland; Honorary Professor, Department of Anaesthesia and Intensive Care, Chinese University of Hong Kong and Adjunct Professor, School of Nursing, QUT.

He has qualifications in anesthesia and intensive care and has set up and been in charge of a number of Intensive Care and Trauma Units in South Africa before coming to Australia in 1997. he currently manages a large multidisciplinary research team with an output of over 120 peer-reviewed articles per annum. He has recently supervised 3 PhD students to completion and is currently supervising 6 PhD, 1 MPhil and 1 MBBS/Hons students. Prof Lipman has been instrumental in developing the anaesthesiology and critical care component of a graduate medical program for Queensland and continues to lecture to medical and postgraduate students.

Prof Lipman is the author of over 320 peer reviewed publications, 26 book chapters and has been invited to deliver over 120 lectures at national and international conferences in many countries across the world. His research interests include all aspects of infection management in intensive care and he has a special interest in the pharmacokinetics of antibiotic dosage, an area in which he received his MD in 2006. His research into antibiotic usage in acute situations has received international recognition and he is regarded as an expert in the field. As such, he and his research team have conducted and presently conduct a number of clinical trials in Australia, New Zealand, Hong Kong, Europe and the UK. Prof Lipman is an editorial board member for 10 international journals, reviews for 23 journals and is an external reviewer for NHMRC project grants and serves on the grant review committee.

Research Interests

  • Antibiotic dosing in critically ill patients
    Severe sepsis is defined as failure of one or more organ systems, most commonly cardiovascular (including shock), respiratory and renal failure, caused by infection. Bacteria, either alone or in combination with other pathogens, are the most common cause of severe sepsis, and Gram-positive and Gram-negative organism account for up to 87% of culture positive episodes. Severe sepsis is a major cause of mortality worldwide. The ANZICS CTG reported that the Australian and New Zealand adult annual incidence of severe sepsis is 77 cases per 100,000,4 which is equivalent to over 17,000 patient episodes per year at an estimated cost per episode of AUD 42,300. Similar population incidence rates have been reported elsewhere. Importantly, 11.8% of all admissions to Australian and New Zealand ICUs are associated with severe sepsis and in-hospital mortality is 37.5%. In patients with septic shock, mortality approaches 60%. The burden of death is almost four times the annual national road toll. The death rate also exceeds other diseases that impact significantly on the Australian community, such as breast and colorectal cancer. In short, severe sepsis is a major public health concern in Australia and improved therapies are needed urgently. My research group is conducting national and international clinical trials investigating the effect of various dosing regimes on health outcomes in critically ill patients.

Research Impacts

My research has been instrumental in changing antibiotic prescribing habits worldwide for critically ill patients, first with aminoglycosides (I did the first and still largest clinical trial to show single daily dosing to be effective) and more recently with beta-lactam antibiotics. Due to critically ill patients having altered pharmacokinetics, using standard antibiotic dosing for these patients is fraught with problems. This has led to the use of Therapeutic Drug Monitoring (TDM) for beta-lactams.

TDM of aminoglycosides and glycopeptides is performed to decrease side-effects of these drugs. Beta-lactams have a large therapeutic ratio and hence measurement of them is infrequent. I helped set up routine TDM of beta-lactam antibiotics at RBWH. I have changed how we dose patients particularly in ICU but also within the wards of RBWH. By means of TDM we have shown we need dose adjustments in 74% of patients to which we administer β-lactam antibiotics in the ICU (Roberts JA et al. Int J Antimicrob Agents 2010;36:332-39). Although scarcely performed world-wide, TDM of beta-lactams is now becoming more commonly performed. We are currently collating data from 5 International centres that also use TDM in an attempt to show outcome benefits of TDM and are starting to publish accordingly (Wong G et al. An international, multi-centre survey of beta-lactam antibiotics TDM practice in intensive care units. J Antimicrob Chemother 2014;69: 1416–1423).


  • MBBCh, University of the Witwatersrand


View all Publications


  • Doctor Philosophy

  • Doctor Philosophy

  • Doctor Philosophy

View all Supervision



Book Chapter

  • Udy, Andrew and Lipman, Jeffrey (2012). Importance of high creatinine clearance for antibacterial treatment in sepsis. In Jordi Rello, Jeffrey Lipman and Thiago Lisboa (Ed.), Sepsis management: PIRO and MODS (pp. 171-197) Berlin, Germany: Springer.

  • Carvajal, Carlos, Rello, Jordi and Lipman, Jeffrey (2011). Candida pneumonia in patients with hematological neoplasia. In Elie Azoulay (Ed.), Pulmonary involvement in patients with hematological malignancies (pp. 349-356) Berlin, Germany: Springer - Verlag. doi:10.1007/978-3-642-15742-4_28

  • Ulldemolins, Marta, Roberts, Jason, Varghese, Julie and Lipman, Jeffrey (2010). Antibiotic dosing in critically ill patients. In Vineet Nayar, J. V. Peter, Roop Kishen and S. Srinivas (Ed.), Critical Care Update 2009 (pp. 128-142) Daryaganj, New Delhi, India: Jaypee Brothers Medical Publishers.

  • Udy, Andrew, Roberts, Jason and Lipman, Jeffrey (2010). Augmented renal clearance: Unraveling the mystery of elevated antibiotic clearance. In J.-L. Vincent (Ed.), Yearbook of Intensive Care and Emergency Medicine 2010 (pp. 495-506) Brussels, Belgium: Springer Verlag. doi:10.1007/978-3-642-10286-8

  • Varghese, Julie M., Roberts, Jason A. and Lipman, Jeffrey (2009). Avoiding toxicity of antibiotics. In Jean-Daniel Chiche and Leanne M. Aitken (Ed.), Patient safety and quality of care in intensive care medicine (pp. 291-304) Berlin, Germany: Medizinisch Wissenschaftliche Verlagsgesellschaft.

  • Udy, Andrew, Roberts, Jason A., Boots, Robert J. and Lipman, Jeffrey (2008). Dose adjustment and pharmacodynamic considerations for antibiotics in severe sepsis and septic shock. In Jordi Rello and Marcos I. Restrepo (Ed.), Sepsis: New strategies for management (pp. 97-102) London: Springer-Verlag. doi:10.1007/978-3-540-79001-3

  • Brown, Anthony F. and Lipman, Jeffrey (2008). Pre-hospital Care. In P. J. Papadakos and B. Lachmann (Ed.), Mechanical ventilation: clinical applications and pathophysiology (pp. 307-319) Philadelphia, United States: Saunders.

  • Roberts, J. A. and Lipman, J. (2007). Dose adjustment and pharmacokinetics of antibiotics in severe sepsis and septic shock. In Jordi Rello, Marin Kollef, Emili Diaz and Alejandro Rodriguez (Ed.), Infectious diseases in critical care 2nd ed. (pp. 122-146) Berlin, Germany; New York, U.S.A.: Springer.

  • Freebairn, R., Cohen, J. and Lipman, J. (2007). Prescription of antimicrobial agents in patients undergoing continuous renal replacement therapy. In Jordi Rello, Marin Kollef, Emili Diaz and Alejandro Rodriguez (Ed.), Infectious diseases in critical care 2nd ed. (pp. 147-159) Berlin & Heidelberg, Germany; New York, USA: Springer - Verlag.

  • Cohen, Jeremy and Lipman, Jeffrey (2006). Use and Abuse of antibiotics. In Nigel R. Webster and Helen F. Galley (Ed.), Anesthesia science (pp. 128-139) Malden, Mass.: Blackwell Pub.

  • Lipman, J. and Saadia, R. (1999). Acute Respiratory Distress Syndrome. In Stephen Westaby and John A. Odell (Ed.), Cardiothoracic Trauma (pp. 295-303) New York US: Oxford Univ. Press.

  • Hopley, M. and Lipman, J. (1999). Tetanus - Pathophysiology. In Webb, A. R., Shapiro, M. J., Singer, M. and Suter, P. M. (Ed.), Oxford Textbook of Critical Care (pp. 510-512) Oxford UK: Oxford University press.

  • Hon, H. and Lipman, J. (1999). Tetanus - Prevention and management. In Webb, A. R., Shapiro, M. J., Singer, M. and Suter, P. M. (Ed.), Oxford Textbook of Critical Care (pp. 512-514) Oxford UK: Oxford Univ. Press.

Journal Article

Conference Publication

Grants (Administered at UQ)

PhD and MPhil Supervision

Note for students: Professor Jeffrey Lipman is not currently available to take on new students.

Current Supervision

Completed Supervision